logo

Cel-Sci Corp. (CVM)



Trade CVM now with
  Date
  Headline
1/4/2021 9:23:37 AM CEL-SCI Says Focusing On First, Advanced Primary Head And Neck Cancer; Awaiting Final Results Of Phase 3 Study
12/30/2020 8:06:06 AM CEL-SCI FY Net Loss $30.3 Mln Vs Net Loss $22.1 Mln Last Year
12/8/2020 7:40:37 PM CEL-SCI Says Underwriters Agrees To Purchase On Firm Commitment Basis Minimum Of 1 Mln Shares At Price Of $14.65/shr
12/7/2020 9:37:02 AM CEL-SCI: Phase 3 Study Is In Final Stage Of Review Which Involves Statistical Analysis Of All Study Data
9/18/2020 9:10:47 AM CEL-SCI Secures European Patent For LEAPS Vaccine In Treatment Of Rheumatoid
8/11/2020 8:42:42 AM CEL-SCI Q3 Net Loss Narrows To $10.2 Mln From $12.1 Mln Prior Year
7/24/2020 8:33:00 AM CEL-SCI Reports Early Results With COVID 19 LEAPS Vaccine/Treatment
6/30/2020 8:36:49 AM CEL-SCI Receives $10 Mln From The Exercise Of Warrants
5/11/2020 8:09:32 AM CEL-SCI Six-mponth Net Loss $14.5 Mln Vs Net Loss $5.2 Mln Last Year
3/24/2020 9:29:13 AM CEL-SCI Increases Previously Announced Bought Deal To $7.7 Mln
3/9/2020 7:58:00 AM CEL-SCI Initiates Development Of Immunotherapy To Treat COVID-19 Coronavirus Infection
2/10/2020 8:08:35 AM CEL-SCI Q1 Net Loss $5.5 Mln Vs Net Income $1.2 Mln Last Year